Found: 80
Select item for more details and to access through your institution.
Glucocorticoid-Induced Leucine Zipper Alleviates Lung Inflammation and Enhances Bacterial Clearance during Pneumococcal Pneumonia.
- Published in:
- Cells (2073-4409), 2022, v. 11, n. 3, p. 532, doi. 10.3390/cells11030532
- By:
- Publication type:
- Article
Type 1 interferon suppresses expression and glucocorticoid induction of glucocorticoid-induced leucine zipper (GILZ).
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.1034880
- By:
- Publication type:
- Article
Immunosuppressant exposure confounds gene expression analysis in systemic lupus erythematosus.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.964263
- By:
- Publication type:
- Article
Reperfusion-induced myocardial dysfunction is prevented by endogenous annexin-A1 and its N-terminal-derived peptide Ac-ANX-A1(2-26).
- Published in:
- 2013
- By:
- Publication type:
- journal article
Reperfusion-induced myocardial dysfunction is prevented by endogenous annexin- A1 and its N-terminal-derived peptide Ac- ANX- A1<sub>2-26</sub>.
- Published in:
- British Journal of Pharmacology, 2013, v. 168, n. 1, p. 238, doi. 10.1111/j.1476-5381.2012.02176.x
- By:
- Publication type:
- Article
Genetic contributions to lupus nephritis in a multi-ethnic cohort of systemic lupus erythematous patients.
- Published in:
- PLoS ONE, 2018, v. 13, n. 6, p. 1, doi. 10.1371/journal.pone.0199003
- By:
- Publication type:
- Article
Rheumatology.
- Published in:
- Medical Journal of Australia, 2002, v. 176, n. 1, p. 41, doi. 10.5694/j.1326-5377.2002.tb04274.x
- By:
- Publication type:
- Article
Comparisons between US norm-based two-component and Japanese norm-based three-component SF-36 summary scores in systemic lupus erythematosus patients.
- Published in:
- Modern Rheumatology, 2023, v. 33, n. 3, p. 517, doi. 10.1093/mr/roac061
- By:
- Publication type:
- Article
Comparisons between US norm-based two-component and Japanese norm-based three-component SF-36 summary scores in systemic lupus erythematosus patients.
- Published in:
- Modern Rheumatology, 2023, v. 33, n. 3, p. 517, doi. 10.1093/mr/roac061
- By:
- Publication type:
- Article
The efficacy and safety of anifrolumab in Japanese patients with systemic lupus erythematosus: TULIP-2 subanalysis.
- Published in:
- Modern Rheumatology, 2023, v. 33, n. 1, p. 134, doi. 10.1093/mr/roac010
- By:
- Publication type:
- Article
Machine learning applied to whole‐blood RNA‐sequencing data uncovers distinct subsets of patients with systemic lupus erythematosus.
- Published in:
- Clinical & Translational Immunology, 2019, v. 8, n. 12, p. N.PAG, doi. 10.1002/cti2.1093
- By:
- Publication type:
- Article
Analysis of serum B cell‐activating factor from the tumor necrosis factor family (BAFF) and its soluble receptors in systemic lupus erythematosus.
- Published in:
- Clinical & Translational Immunology, 2019, v. 8, n. 4, p. N.PAG, doi. 10.1002/cti2.1047
- By:
- Publication type:
- Article
Analysis of serum macrophage migration inhibitory factor and D‐dopachrome tautomerase in systemic sclerosis.
- Published in:
- Clinical & Translational Immunology, 2018, v. 7, n. 12, p. N.PAG, doi. 10.1002/cti2.1042
- By:
- Publication type:
- Article
Analysis of serum interleukin(IL)‐1α, IL‐1β and IL‐18 in patients with systemic sclerosis.
- Published in:
- Clinical & Translational Immunology, 2019, v. 8, n. 4, p. N.PAG, doi. 10.1002/cti2.1045
- By:
- Publication type:
- Article
Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: a post hoc analysis of the TULIP-1 and TULIP-2 trials.
- Published in:
- Rheumatology, 2023, v. 62, n. 4, p. 1526, doi. 10.1093/rheumatology/keac491
- By:
- Publication type:
- Article
Fibromyalgia, mood disorders, cognitive test results, cognitive symptoms and quality of life in systemic lupus erythematosus.
- Published in:
- Rheumatology, 2023, v. 62, n. 1, p. 190, doi. 10.1093/rheumatology/keac207
- By:
- Publication type:
- Article
Easy-BILAG: as easy as ABC?
- Published in:
- 2022
- By:
- Publication type:
- Editorial
Filgotinib in cutaneous lupus: is a negative positive?
- Published in:
- 2022
- By:
- Publication type:
- Editorial
Relationship of anifrolumab pharmacokinetics with efficacy and safety in patients with systemic lupus erythematosus.
- Published in:
- Rheumatology, 2022, v. 61, n. 5, p. 1900, doi. 10.1093/rheumatology/keab704
- By:
- Publication type:
- Article
Measurement of specific organ domains in lupus randomized controlled trials: a scoping review.
- Published in:
- Rheumatology, 2022, v. 61, n. 4, p. 1341, doi. 10.1093/rheumatology/keab777
- By:
- Publication type:
- Article
Safety and clinical activity of atacicept in the long-term extension of the phase 2b ADDRESS II study in systemic lupus erythematosus.
- Published in:
- Rheumatology, 2021, v. 60, n. 11, p. 5379, doi. 10.1093/rheumatology/keab115
- By:
- Publication type:
- Article
Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study.
- Published in:
- Rheumatology, 2020, v. 59, n. 10, p. 2930, doi. 10.1093/rheumatology/keaa029
- By:
- Publication type:
- Article
It hasn't gone away: the problem of glucocorticoid use in lupus remains.
- Published in:
- Rheumatology, 2017, v. 56, p. i114, doi. 10.1093/rheumatology/kew406
- By:
- Publication type:
- Article
Targeting Interferon Signalling in Systemic Lupus Erythematosus: Lessons Learned.
- Published in:
- Drugs, 2024, v. 84, n. 6, p. 625, doi. 10.1007/s40265-024-02043-2
- By:
- Publication type:
- Article
Manipulation of B-cell responses with histone deacetylase inhibitors.
- Published in:
- Nature Communications, 2015, v. 6, n. 4, p. 6838, doi. 10.1038/ncomms7838
- By:
- Publication type:
- Article
Analysis of Serum Interleukin (IL)-iβ and IL-18 in Systemic Lupus Erythematosus.
- Published in:
- Frontiers in Immunology, 2018, p. 1, doi. 10.3389/fimmu.2018.01250
- By:
- Publication type:
- Article
Identifying lupus Patient Subsets Through Immune Cell Deconvolution of Gene Expression Data in Two Atacicept Phase II Studies.
- Published in:
- ACR Open Rheumatology, 2023, v. 5, n. 10, p. 536, doi. 10.1002/acr2.11594
- By:
- Publication type:
- Article
A Randomized, Placebo‐Controlled Phase III Extension Trial of the Long‐Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus.
- Published in:
- Arthritis & Rheumatology, 2023, v. 75, n. 2, p. 253, doi. 10.1002/art.42392
- By:
- Publication type:
- Article
What Does It Mean to Be a British Isles Lupus Assessment Group–Based Composite Lupus Assessment Responder? Post Hoc Analysis of Two Phase III Trials.
- Published in:
- Arthritis & Rheumatology, 2021, v. 73, n. 11, p. 2059, doi. 10.1002/art.41778
- By:
- Publication type:
- Article
Brief Report: Interleukin-38 Exerts Antiinflammatory Functions and Is Associated With Disease Activity in Systemic Lupus Erythematosus.
- Published in:
- Arthritis & Rheumatology, 2015, v. 67, n. 12, p. 3219, doi. 10.1002/art.39328
- By:
- Publication type:
- Article
Bcl-2 Antagonists Kill Plasmacytoid Dendritic Cells From Lupus-Prone Mice and Dampen Interferon-α Production.
- Published in:
- 2015
- By:
- Publication type:
- Journal Article
Bcl-2 Antagonists Kill Plasmacytoid Dendritic Cells From Lupus-Prone Mice and Dampen Interferon-α Production.
- Published in:
- Arthritis & Rheumatology, 2015, v. 67, n. 3, p. 797, doi. 10.1002/art.38966
- By:
- Publication type:
- Article
Macrophage Migration Inhibitory Factor Inhibits the Antiinflammatory Effects of Glucocorticoids via Glucocorticoid-Induced Leucine Zipper.
- Published in:
- Arthritis & Rheumatology, 2014, v. 66, n. 8, p. 2059, doi. 10.1002/art.38689
- By:
- Publication type:
- Article
Endogenous Myeloperoxidase Is a Mediator of Joint Inflammation and Damage in Experimental Arthritis.
- Published in:
- Arthritis & Rheumatology, 2014, v. 66, n. 4, p. 907, doi. 10.1002/art.38299
- By:
- Publication type:
- Article
Macrophage migration inhibitory factor is required for NLRP3 inflammasome activation.
- Published in:
- Nature Communications, 2018, v. 9, n. 1, p. 1, doi. 10.1038/s41467-018-04581-2
- By:
- Publication type:
- Article
Patterns and prevalence of cognitive dysfunction in systemic lupus erythematosus.
- Published in:
- Journal of the International Neuropsychological Society, 2023, v. 29, n. 5, p. 421, doi. 10.1017/S1355617722000418
- By:
- Publication type:
- Article
Rare variants in non-coding regulatory regions of the genome that affect gene expression in systemic lupus erythematosus.
- Published in:
- Scientific Reports, 2019, v. 9, n. 1, p. N.PAG, doi. 10.1038/s41598-019-51864-9
- By:
- Publication type:
- Article
MIF: Implications in the Pathoetiology of Systemic Lupus erythematosus.
- Published in:
- Frontiers in Immunology, 2015, v. 6, p. 1, doi. 10.3389/fimmu.2015.00577
- By:
- Publication type:
- Article
Pro-Inflammatory Action of MIF in Acute Myocardial Infarction via Activation of Peripheral Blood Mononuclear Cells.
- Published in:
- PLoS ONE, 2013, v. 8, n. 10, p. 1, doi. 10.1371/journal.pone.0076206
- By:
- Publication type:
- Article
Glucocorticoid-Induced Leucine Zipper (GILZ) Regulates Testicular FOXO1 Activity and Spermatogonial Stem Cell (SSC) Function.
- Published in:
- PLoS ONE, 2013, v. 8, n. 3, p. 1, doi. 10.1371/journal.pone.0059149
- By:
- Publication type:
- Article
Regulation of Annexin I in Rheumatoid Synovial Cells by Glucocorticoids and Interleukin-1.
- Published in:
- Mediators of Inflammation, 2006, v. 2006, n. 2, p. 1, doi. 10.1155/MI/2006/73835
- By:
- Publication type:
- Article
Regulation of Annexin I in Rheumatoid Synovial Cells by Glucocorticoids and Interleukin-1.
- Published in:
- Mediators of Inflammation, 2006, v. 2006, p. 1, doi. 10.1155/MI/2006/73835
- By:
- Publication type:
- Article
Annexin I and dexamethasone effects on phospholipase and cyclooxygenase activity in human synoviocytes.
- Published in:
- Mediators of Inflammation, 2000, v. 9, n. 3/4, p. 125, doi. 10.1080/09629350020018357
- By:
- Publication type:
- Article
Correction: Targeting DORIS Remission and LLDAS in SLE: A Review.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
Targeting DORIS Remission and LLDAS in SLE: A Review.
- Published in:
- Rheumatology & Therapy, 2023, v. 10, n. 6, p. 1459, doi. 10.1007/s40744-023-00601-w
- By:
- Publication type:
- Article
Clinical associations of IL-10 and IL-37 in systemic lupus erythematosus.
- Published in:
- Scientific Reports, 2016, p. 34604, doi. 10.1038/srep34604
- By:
- Publication type:
- Article
Relationship Between Anifrolumab Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Moderate to Severe Systemic Lupus Erythematosus.
- Published in:
- Journal of Clinical Pharmacology, 2022, v. 62, n. 9, p. 1094, doi. 10.1002/jcph.2054
- By:
- Publication type:
- Article
Systemic lupus erythematosus: a clinical update.
- Published in:
- Internal Medicine Journal, 2021, v. 51, n. 8, p. 1219, doi. 10.1111/imj.15448
- By:
- Publication type:
- Article
Investigating immunoregulatory effects of myeloid cell autophagy in acute and chronic inflammation.
- Published in:
- Immunology & Cell Biology, 2022, v. 100, n. 8, p. 605, doi. 10.1111/imcb.12562
- By:
- Publication type:
- Article
Necrotic cell death increases the release of macrophage migration inhibitory factor by monocytes/macrophages.
- Published in:
- Immunology & Cell Biology, 2020, v. 98, n. 9, p. 782, doi. 10.1111/imcb.12376
- By:
- Publication type:
- Article